Kling Biotherapeutics utilizes a proprietary B cell immortalization technology to discover novel therapeutic targets and fully human antibodies directly from patient-derived B cells, addressing the need for effective antibody-based treatments for various diseases. Their platform has successfully identified neutralizing antibodies for infectious diseases and is advancing a pipeline of oncology programs, including a Phase 1 clinical trial for a first-in-class CD9 antibody.
Funding
Funding not disclosed
Founders
Product
Problem
Developing effective antibody-based treatments is challenging due to the difficulty of identifying novel therapeutic targets and generating fully human antibodies, particularly for complex diseases like cancer and emerging infectious diseases. Traditional target discovery approaches often miss unique epitopes and novel targets inaccessible through conventional methods.
Solution
Kling Biotherapeutics utilizes a proprietary B cell immortalization technology, Kling-Select and Kling-Evolve, to discover novel therapeutic targets and fully human antibodies directly from patient-derived B cells. This clinically-validated platform identifies antibodies from patients with exceptional clinical responses, enabling the discovery of neutralizing antibodies for infectious diseases and a portfolio of novel target-antibody pairs for oncology. Kling-Evolve facilitates the ex vivo affinity maturation of B cell clones, allowing for rapid evolution of neutralizing antibodies against emerging viral variants or for affinity and selectivity improvement of oncology assets. The unbiased nature of the platform allows identification of novel targets and unique epitopes inaccessible to traditional target discovery approaches.
Target Audience
The primary audience includes researchers and pharmaceutical companies focused on developing antibody-based therapeutics for infectious diseases and cancer.
Features
- Kling-Select: Proprietary B cell immortalization technology for identifying novel therapeutic targets and antibody binders.
- Identification of fully human antibodies directly from patient-derived B cells.
- Application to peripheral and tumor-infiltrating B cells derived from cancer patients.
- Kling-Evolve: Ex vivo affinity maturation of B cell clones against targets of interest.
- Rapid evolution of neutralizing antibodies against emerging viral variants.
- Pipeline of oncology programs, including a Phase 1 clinical trial for a first-in-class CD9 antibody (KBA1412).